MAYNE PHARMA GROUP LIMITED - Announcements

Market Cap $398.1M Add to my watchlist

Healthcare

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused... Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.More

RCE'S BREAKTHROUGH

Synthetic anti-infective developer Recce Pharmaceuticals Ltd (ASX:RCE) has made inroads for recognition of its RECCE® 327 Gel (or R327G) as a topical treatment for burn wound infections, gaining a US$2 million grant from the US Department of Defense...

Announcements

Filter Results

All Price Sensitive Only

MYX	2018 Full Year Results Media Release	PRICE SENSITIVE	24/08/18	444.47KB	Share
MYX	Full Year Statutory Accounts	PRICE SENSITIVE	24/08/18	7.43MB	Share
MYX	Appendix 3B		27/07/18	698.8KB	Share
MYX	Mayne Pharma acquires generic Efudex in the US	PRICE SENSITIVE	23/07/18	269.46KB	Share
MYX	Lapse of employee options and option exercise		16/07/18	392.61KB	Share
MYX	Initial Director's Interest Notice		28/06/18	511.11KB	Share
MYX	Mayne Pharma further strengthens Board with new Director		28/06/18	249.85KB	Share
MYX	Appendix 3B		20/06/18	696.34KB	Share
MYX	Appendix 3B		15/06/18	1.08MB	Share
MYX	Ceasing to be a substantial holder		07/06/18	44.77KB	Share
MYX	Appendix 3B		06/06/18	1013.65KB	Share
MYX	Revised Securities Trading Policy		31/05/18	454.4KB	Share
MYX	Initial Director's Interest Notice		30/05/18	508.84KB	Share
MYX	Mayne Pharma strengthens Board with new Director		30/05/18	251.49KB	Share
MYX	SUBA-Itraconazole NDA accepted for review by US FDA	PRICE SENSITIVE	02/05/18	390.44KB	Share
MYX	Appendix 3B		01/05/18	697.7KB	Share
MYX	Mayne Pharma opens new US manufacturing facility	PRICE SENSITIVE	18/04/18	267.75KB	Share
MYX	Mayne Pharma launches Amiodarone 200mg tablets in the US	PRICE SENSITIVE	17/04/18	256.29KB	Share
MYX	Appendix 3B		10/04/18	698.7KB	Share
MYX	Appendix 3B		09/04/18	145.14KB	Share
MYX	Change in substantial holding		28/03/18	246.06KB	Share
MYX	Mayne Pharma launches generic Quartette in the US		27/03/18	385.59KB	Share
MYX	Appendix 3B and lapse of employee options		20/03/18	1.03MB	Share
MYX	Mayne Pharma's generic NuvaRing accepted for filing by FDA	PRICE SENSITIVE	20/03/18	391.96KB	Share
MYX	Mayne Pharma launches doxycycline IR capsules in the US	PRICE SENSITIVE	16/03/18	383.19KB	Share
MYX	First generic launch of Ritalin LA 10mg capsules in the US	PRICE SENSITIVE	01/03/18	98.7KB	Share
MYX	Becoming a substantial holder		27/02/18	60.69KB	Share
MYX	2018 Half Year Investor Presentation	PRICE SENSITIVE	23/02/18	1.74MB	Share
MYX	2018 Half Year Media Release	PRICE SENSITIVE	23/02/18	437.47KB	Share
MYX	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/18	1.4MB	Share
MYX	Appendix 3B		20/02/18	697.53KB	Share
MYX	Employee share scheme buyback final notice		19/02/18	1.11MB	Share
MYX	Appendix 3C - Employee Loan Scheme Buy Back		02/02/18	269.56KB	Share
MYX	Change of Director's Interest Notice		22/12/17	92.18KB	Share
MYX	Appendix 3B		15/12/17	695.9KB	Share
MYX	Change of Director's Interest Notice		07/12/17	578.5KB	Share
MYX	Appendix 3B		07/12/17	696.72KB	Share
MYX	Appendix 3B		30/11/17	114.2KB	Share
MYX	Results of Meeting		28/11/17	411.35KB	Share
MYX	2017 AGM Presentation		28/11/17	1.21MB	Share
MYX	2017 CEO's Speech	PRICE SENSITIVE	28/11/17	297.96KB	Share
MYX	2017 AGM Chairman's Speech		28/11/17	261.76KB	Share
MYX	Mayne Pharma launches clozapine tablets in the US	PRICE SENSITIVE	09/11/17	247.68KB	Share
MYX	Appendix 3B		02/11/17	698.13KB	Share
MYX	Notice of Annual General Meeting/Proxy Form		20/10/17	2.82MB	Share
MYX	Appendix 4G		19/10/17	374.88KB	Share
MYX	2017 Corporate Governance Statement		19/10/17	344.46KB	Share
MYX	2017 Annual Report		19/10/17	4MB	Share
MYX	Appendix 3B		11/10/17	698.45KB	Share
MYX	Mayne Pharma adds two products to its Australian portfolio	PRICE SENSITIVE	15/09/17	427.72KB	Share
MYX	Appendix 3B and lapse of employee options		08/09/17	1.06MB	Share
MYX	Full Year Statutory Accounts		30/08/17	1.85MB	Share
MYX	Change of Director's Interest Notice		29/08/17	46.47KB	Share
MYX	Ceasing to be a substantial holder		28/08/17	264.98KB	Share
MYX	2017 Full Year Results Investor Presentation		25/08/17	1.87MB	Share
MYX	2017 Full Year Results Media Release		25/08/17	308.34KB	Share
MYX	Preliminary Final Report	PRICE SENSITIVE	25/08/17	1.5MB	Share
MYX	Ceasing to be a substantial holder from CBA		16/08/17	87.2KB	Share
MYX	Change in substantial holding from CBA		14/08/17	153.43KB	Share
MYX	Change in substantial holding		08/08/17	257.75KB	Share
MYX	Mayne Pharma market update	PRICE SENSITIVE	08/08/17	447.89KB	Share
MYX	Change in substantial holding from CBA		31/07/17	278.41KB	Share
MYX	Appendix 3B		14/07/17	111.24KB	Share
MYX	Appendix 3B		27/06/17	735.89KB	Share
MYX	Change of Director's Interest Notice		27/06/17	575.29KB	Share
MYX	FDA approval and first generic launch of Acticlate tablets	PRICE SENSITIVE	15/06/17	96.5KB	Share
MYX	Appendix 3B		09/06/17	110.36KB	Share
MYX	2016 Sustainability Report		08/06/17	8.96MB	Share
MYX	Appendix 3B		26/05/17	735.46KB	Share
MYX	Change in substantial holding		24/05/17	221.03KB	Share
MYX	Appendix 3B		22/05/17	724.92KB	Share
MYX	Change of Director's Interest Notice		11/05/17	430.93KB	Share
MYX	Appendix 3B		10/05/17	723.87KB	Share
MYX	Appendix 3B		08/05/17	724.05KB	Share
MYX	Response to ASX Aware Letter	PRICE SENSITIVE	04/05/17	653.95KB	Share
MYX	Becoming a substantial holder		03/05/17	292.97KB	Share
MYX	Ceasing to be a substantial holder from CGF		03/05/17	125.28KB	Share
MYX	Clarification statement	PRICE SENSITIVE	02/05/17	89.14KB	Share
MYX	Investor Day - Presentation		01/05/17	14.48MB	Share
MYX	Becoming a substantial holder from CGF		28/04/17	326.44KB	Share
MYX	Mayne Pharma to host Investor Day on May 1st, 2017		26/04/17	244.65KB	Share
MYX	Becoming a substantial holder		11/04/17	283.05KB	Share
MYX	Appendix 3B		10/04/17	309.21KB	Share
MYX	Appendix 3B		28/03/17	724.09KB	Share
MYX	Change of Director's Interest Notice		17/03/17	597.55KB	Share
MYX	Ceasing to be a substantial holder		13/03/17	153.53KB	Share
MYX	Becoming a substantial holder		09/03/17	268.11KB	Share
MYX	Mayne Pharma appoints new Group CFO and Company Secretary		09/03/17	248.49KB	Share
MYX	Mayne Pharma acquires rights to generic Duragesic in the US	PRICE SENSITIVE	09/03/17	268.96KB	Share
MYX	Change of Director's Interest Notice		08/03/17	596.18KB	Share
MYX	Appendix 3B		06/03/17	724.44KB	Share
MYX	License and supply agreement for generic Nuvaring in the US	PRICE SENSITIVE	28/02/17	103.27KB	Share
MYX	2017 Half Year Investor Presentation		24/02/17	1.79MB	Share
MYX	2017 Half Year Media Release	PRICE SENSITIVE	24/02/17	312.52KB	Share
MYX	Half Yearly Report and Accounts	PRICE SENSITIVE	24/02/17	1.35MB	Share
MYX	Appendix 3B		20/02/17	731.15KB	Share
MYX	Mayne Pharma launches Butalbital / APAP tablets in the US	PRICE SENSITIVE	16/02/17	246.53KB	Share
MYX	Mayne Pharma announces leadership changes		16/01/17	106.72KB	Share
MYX	Mayne Pharma launches Amiodarone 100mg tablets	PRICE SENSITIVE	13/01/17	95.19KB	Share
MYX	Appendix 3B		12/01/17	316.47KB	Share

MYX 2018 Full Year Results Media Release
24/08/18	PRICE SENSITIVE	444.47KB	Share
MYX Full Year Statutory Accounts
24/08/18	PRICE SENSITIVE	7.43MB	Share
MYX Appendix 3B
27/07/18		698.8KB	Share
MYX Mayne Pharma acquires generic Efudex in the US
23/07/18	PRICE SENSITIVE	269.46KB	Share
MYX Lapse of employee options and option exercise
16/07/18		392.61KB	Share
MYX Initial Director's Interest Notice
28/06/18		511.11KB	Share
MYX Mayne Pharma further strengthens Board with new Director
28/06/18		249.85KB	Share
MYX Appendix 3B
20/06/18		696.34KB	Share
MYX Appendix 3B
15/06/18		1.08MB	Share
MYX Ceasing to be a substantial holder
07/06/18		44.77KB	Share
MYX Appendix 3B
06/06/18		1013.65KB	Share
MYX Revised Securities Trading Policy
31/05/18		454.4KB	Share
MYX Initial Director's Interest Notice
30/05/18		508.84KB	Share
MYX Mayne Pharma strengthens Board with new Director
30/05/18		251.49KB	Share
MYX SUBA-Itraconazole NDA accepted for review by US FDA
02/05/18	PRICE SENSITIVE	390.44KB	Share
MYX Appendix 3B
01/05/18		697.7KB	Share
MYX Mayne Pharma opens new US manufacturing facility
18/04/18	PRICE SENSITIVE	267.75KB	Share
MYX Mayne Pharma launches Amiodarone 200mg tablets in the US
17/04/18	PRICE SENSITIVE	256.29KB	Share
MYX Appendix 3B
10/04/18		698.7KB	Share
MYX Appendix 3B
09/04/18		145.14KB	Share
MYX Change in substantial holding
28/03/18		246.06KB	Share
MYX Mayne Pharma launches generic Quartette in the US
27/03/18		385.59KB	Share
MYX Appendix 3B and lapse of employee options
20/03/18		1.03MB	Share
MYX Mayne Pharma's generic NuvaRing accepted for filing by FDA
20/03/18	PRICE SENSITIVE	391.96KB	Share
MYX Mayne Pharma launches doxycycline IR capsules in the US
16/03/18	PRICE SENSITIVE	383.19KB	Share
MYX First generic launch of Ritalin LA 10mg capsules in the US
01/03/18	PRICE SENSITIVE	98.7KB	Share
MYX Becoming a substantial holder
27/02/18		60.69KB	Share
MYX 2018 Half Year Investor Presentation
23/02/18	PRICE SENSITIVE	1.74MB	Share
MYX 2018 Half Year Media Release
23/02/18	PRICE SENSITIVE	437.47KB	Share
MYX Half Yearly Report and Accounts
23/02/18	PRICE SENSITIVE	1.4MB	Share
MYX Appendix 3B
20/02/18		697.53KB	Share
MYX Employee share scheme buyback final notice
19/02/18		1.11MB	Share
MYX Appendix 3C - Employee Loan Scheme Buy Back
02/02/18		269.56KB	Share
MYX Change of Director's Interest Notice
22/12/17		92.18KB	Share
MYX Appendix 3B
15/12/17		695.9KB	Share
MYX Change of Director's Interest Notice
07/12/17		578.5KB	Share
MYX Appendix 3B
07/12/17		696.72KB	Share
MYX Appendix 3B
30/11/17		114.2KB	Share
MYX Results of Meeting
28/11/17		411.35KB	Share
MYX 2017 AGM Presentation
28/11/17		1.21MB	Share
MYX 2017 CEO's Speech
28/11/17	PRICE SENSITIVE	297.96KB	Share
MYX 2017 AGM Chairman's Speech
28/11/17		261.76KB	Share
MYX Mayne Pharma launches clozapine tablets in the US
09/11/17	PRICE SENSITIVE	247.68KB	Share
MYX Appendix 3B
02/11/17		698.13KB	Share
MYX Notice of Annual General Meeting/Proxy Form
20/10/17		2.82MB	Share
MYX Appendix 4G
19/10/17		374.88KB	Share
MYX 2017 Corporate Governance Statement
19/10/17		344.46KB	Share
MYX 2017 Annual Report
19/10/17		4MB	Share
MYX Appendix 3B
11/10/17		698.45KB	Share
MYX Mayne Pharma adds two products to its Australian portfolio
15/09/17	PRICE SENSITIVE	427.72KB	Share
MYX Appendix 3B and lapse of employee options
08/09/17		1.06MB	Share
MYX Full Year Statutory Accounts
30/08/17		1.85MB	Share
MYX Change of Director's Interest Notice
29/08/17		46.47KB	Share
MYX Ceasing to be a substantial holder
28/08/17		264.98KB	Share
MYX 2017 Full Year Results Investor Presentation
25/08/17		1.87MB	Share
MYX 2017 Full Year Results Media Release
25/08/17		308.34KB	Share
MYX Preliminary Final Report
25/08/17	PRICE SENSITIVE	1.5MB	Share
MYX Ceasing to be a substantial holder from CBA
16/08/17		87.2KB	Share
MYX Change in substantial holding from CBA
14/08/17		153.43KB	Share
MYX Change in substantial holding
08/08/17		257.75KB	Share
MYX Mayne Pharma market update
08/08/17	PRICE SENSITIVE	447.89KB	Share
MYX Change in substantial holding from CBA
31/07/17		278.41KB	Share
MYX Appendix 3B
14/07/17		111.24KB	Share
MYX Appendix 3B
27/06/17		735.89KB	Share
MYX Change of Director's Interest Notice
27/06/17		575.29KB	Share
MYX FDA approval and first generic launch of Acticlate tablets
15/06/17	PRICE SENSITIVE	96.5KB	Share
MYX Appendix 3B
09/06/17		110.36KB	Share
MYX 2016 Sustainability Report
08/06/17		8.96MB	Share
MYX Appendix 3B
26/05/17		735.46KB	Share
MYX Change in substantial holding
24/05/17		221.03KB	Share
MYX Appendix 3B
22/05/17		724.92KB	Share
MYX Change of Director's Interest Notice
11/05/17		430.93KB	Share
MYX Appendix 3B
10/05/17		723.87KB	Share
MYX Appendix 3B
08/05/17		724.05KB	Share
MYX Response to ASX Aware Letter
04/05/17	PRICE SENSITIVE	653.95KB	Share
MYX Becoming a substantial holder
03/05/17		292.97KB	Share
MYX Ceasing to be a substantial holder from CGF
03/05/17		125.28KB	Share
MYX Clarification statement
02/05/17	PRICE SENSITIVE	89.14KB	Share
MYX Investor Day - Presentation
01/05/17		14.48MB	Share
MYX Becoming a substantial holder from CGF
28/04/17		326.44KB	Share
MYX Mayne Pharma to host Investor Day on May 1st, 2017
26/04/17		244.65KB	Share
MYX Becoming a substantial holder
11/04/17		283.05KB	Share
MYX Appendix 3B
10/04/17		309.21KB	Share
MYX Appendix 3B
28/03/17		724.09KB	Share
MYX Change of Director's Interest Notice
17/03/17		597.55KB	Share
MYX Ceasing to be a substantial holder
13/03/17		153.53KB	Share
MYX Becoming a substantial holder
09/03/17		268.11KB	Share
MYX Mayne Pharma appoints new Group CFO and Company Secretary
09/03/17		248.49KB	Share
MYX Mayne Pharma acquires rights to generic Duragesic in the US
09/03/17	PRICE SENSITIVE	268.96KB	Share
MYX Change of Director's Interest Notice
08/03/17		596.18KB	Share
MYX Appendix 3B
06/03/17		724.44KB	Share
MYX License and supply agreement for generic Nuvaring in the US
28/02/17	PRICE SENSITIVE	103.27KB	Share
MYX 2017 Half Year Investor Presentation
24/02/17		1.79MB	Share
MYX 2017 Half Year Media Release
24/02/17	PRICE SENSITIVE	312.52KB	Share
MYX Half Yearly Report and Accounts
24/02/17	PRICE SENSITIVE	1.35MB	Share
MYX Appendix 3B
20/02/17		731.15KB	Share
MYX Mayne Pharma launches Butalbital / APAP tablets in the US
16/02/17	PRICE SENSITIVE	246.53KB	Share
MYX Mayne Pharma announces leadership changes
16/01/17		106.72KB	Share
MYX Mayne Pharma launches Amiodarone 100mg tablets
13/01/17	PRICE SENSITIVE	95.19KB	Share
MYX Appendix 3B
12/01/17		316.47KB	Share

REFRESH

First 3 4 5 6 7

(20min delay)
Last $4.68		Change -0.050(1.06%)		Mkt cap ! $398.1M

Open	High	Low	Value	Volume
$4.67	$4.76	$4.65	$606.2K	128.8K

Buyers (Bids)

No.	Vol.	Price($)
1	48	$4.68

Sellers (Offers)

Price($)	Vol.	No.
$4.70	105	1

View Market Depth

No.	Vol.	Price($)
1	48	4.680
3	3637	4.660
3	9938	4.650
2	794	4.640
1	105	4.630

Price($)	Vol.	No.
4.700	105	1
4.710	105	1
4.720	794	2
4.730	794	2
4.740	794	2

Last trade - 16.10pm 22/07/2024 (20 minute delay)


Last $4.69		Change -0.050 ( 0.52 %)
Open	High	Low	Volume
$4.62	$4.76	$4.62	29282
Last updated 15.59pm 22/07/2024 ?

MYX (ASX) Chart

MAYNE PHARMA GROUP LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories